Syntara Ltd (SNT) - Total Liabilities
Based on the latest financial reports, Syntara Ltd (SNT) has total liabilities worth AU$5.42 Million AUD (≈ $3.84 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Syntara Ltd (SNT) net asset momentum to track the company's year-over-year net asset growth rate.
Syntara Ltd - Total Liabilities Trend (2003–2025)
This chart illustrates how Syntara Ltd's total liabilities have evolved over time, based on quarterly financial data. See Syntara Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Syntara Ltd Competitors by Total Liabilities
The table below lists competitors of Syntara Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wellbiotec Co. Ltd.
KO:010600
|
Korea | ₩11.76 Billion |
|
Century Casinos Inc
NASDAQ:CNTY
|
USA | $1.15 Billion |
|
Ferroamp Elektronik AB
ST:FERRO
|
Sweden | Skr78.55 Million |
|
Raval ACS Ltd
TA:RVL
|
Israel | ILA110.61 Million |
|
MUI Properties Bhd
KLSE:3913
|
Malaysia | RM330.46 Million |
|
Pre-Built Public Company Limited
BK:PREB
|
Thailand | ฿3.89 Billion |
|
CMR S.A.B. de C.V
MX:CMRB
|
Mexico | MX$3.23 Billion |
|
Plus500 Ltd
LSE:PLUS
|
UK | GBX448.90 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Syntara Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Syntara Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Syntara Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Syntara Ltd (2003–2025)
The table below shows the annual total liabilities of Syntara Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$5.42 Million ≈ $3.84 Million |
-4.84% |
| 2024-06-30 | AU$5.70 Million ≈ $4.03 Million |
-60.59% |
| 2023-06-30 | AU$14.47 Million ≈ $10.24 Million |
+0.59% |
| 2022-06-30 | AU$14.38 Million ≈ $10.18 Million |
-53.22% |
| 2021-06-30 | AU$30.75 Million ≈ $21.75 Million |
-9.53% |
| 2020-06-30 | AU$33.98 Million ≈ $24.05 Million |
-10.22% |
| 2019-06-30 | AU$37.85 Million ≈ $26.78 Million |
-2.89% |
| 2018-06-30 | AU$38.98 Million ≈ $27.58 Million |
-7.00% |
| 2017-06-30 | AU$41.91 Million ≈ $29.66 Million |
-6.29% |
| 2016-06-30 | AU$44.73 Million ≈ $31.65 Million |
-3.27% |
| 2015-06-30 | AU$46.24 Million ≈ $32.72 Million |
-5.02% |
| 2014-06-30 | AU$48.68 Million ≈ $34.44 Million |
+9.68% |
| 2013-06-30 | AU$44.38 Million ≈ $31.41 Million |
+102.70% |
| 2012-06-30 | AU$21.90 Million ≈ $15.49 Million |
-7.77% |
| 2011-06-30 | AU$23.74 Million ≈ $16.80 Million |
-7.80% |
| 2010-06-30 | AU$25.75 Million ≈ $18.22 Million |
-2.11% |
| 2009-06-30 | AU$26.31 Million ≈ $18.61 Million |
+343.76% |
| 2008-06-30 | AU$5.93 Million ≈ $4.19 Million |
-2.64% |
| 2007-06-30 | AU$6.09 Million ≈ $4.31 Million |
+13.20% |
| 2006-06-30 | AU$5.38 Million ≈ $3.81 Million |
+127.09% |
| 2005-06-30 | AU$2.37 Million ≈ $1.68 Million |
+59.96% |
| 2004-06-30 | AU$1.48 Million ≈ $1.05 Million |
+144.96% |
| 2003-06-30 | AU$604.50K ≈ $427.72K |
-- |
About Syntara Ltd
Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more